Markets

Roche, AbbVie Get FDA Approval for Venclexta Label Expansion

A generic image of a person on their laptop
Credit: Shutterstock photo

Roche RHHBY and partner AbbVie, Inc. ABBV announced that the FDA has granted accelerated approval for a label expansion of Venclexta (venetoclax).

The FDA granted accelerated approval to Venclexta in combination with a hypomethylating agent (azacitidine or decitabine) or low-dose cytarabine (LDAC) for the treatment of patients suffering from newly-diagnosed acute myeloid leukaemia (AML) who are aged 75 years or older or those ineligible for intensive induction chemotherapy due to coexisting medical conditions.

The approval was based on positive results from the M14-358 and the M14-387 studies, which showed durable remissions in patients suffering from newly-diagnosed AML.

Consequently, Venclexta now is indicated for all AML patients regardless of subtypes.

The FDA generally grants accelerated approval to a drug that fills an unmet medical need for a serious condition. Continued approval for this indication may be contingent upon verification and description of clinical benefit observed in confirmatory trials.

Earlier, the FDA had granted Priority Review to the supplemental New Drug Application (sNDA) for Venclexta. The FDA had earlier granted two Breakthrough Therapy designations to Venclexta for the treatment of patients with previously untreated AML who are ineligible for intensive chemotherapy, either in combination with a hypomethylating agent or LDAC, based on results from the two studies.

In June 2018, the FDA granted regular approval to Venclexta for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

The label expansion of the drug will expand the patient population, which, in turn, should boost sales.

While Roche and AbbVie commercialize the drug in the United States, the latter is responsible for the same outside the United States.

Shares of Roche have gained 1.3% so far this year compared with the industry's growth of 10.8%.

Roche is a leader in oncology market with a diverse portfolio. Approval of new drugs and potential label expansion of existing drugs bode well for Roche, as its legacy drugs like Avastin, Herceptin and MabThera are facing competition from biosimilars. Novartis NVS has already launched its biosimilar version of Rituxan/ MabThera in Europe. Amgen AMGN too has got its biosimilar of Avastin.

Zacks Rank

Roche currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AbbVie Inc. (ABBV): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report

Roche Holding AG (RHHBY): Free Stock Analysis Report

Amgen Inc. (AMGN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABBV NVS RHHBY AMGN

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More